Sequence variants underlying severe combined immunodeficiency and leukocyte adhesion deficiency type 1 in six consanguineous families
Immunogenetics · 2024
DOI: 10.1007/s00251-024-01353-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunogenetics, 2024. Verfasst von Hajra Fayyaz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University Islamabad, Islamabad, Pakistan. Hauptthemen laut MEDLINE: Leukocyte-Adhesion Deficiency Syndrome, Severe Combined Immunodeficiency, Consanguinity, Pedigree. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Inborn errors of immunity (IEI) are defined as genetic disorders affecting the immune system and resulting in diverse clinical signs and symptoms. Despite the lack of diagnosis and unavailability of IEI estimation in the Pakistani population, consanguinity is exacerbating its prevalence. The current study focuses on severe combined immunodeficiency (SCID) and leukocyte adhesion deficiency type 1 (LAD1). SCID is associated with the life-threatening symptoms developing at post-birth. LAD1 is clinically characterized by recurrent bacterial infections related to the skin, mouth, and respiratory tract owing to impaired leukocytes. Herein, in six consanguineous families, flow cytometry was used to evaluate the patient's immune status. Whole-exome sequencing (WES) was then conducted to search for the causative variations in immunodeficiency genes. Sanger sequencing was used to assess the segregation of the variants with the disorder within the families. Sequence analysis revealed five homozygous variants in four different causative genes. This included four novel nonsense variants in CD70 p.(Thr126Profs*33), CD3e p.(Trp151*), IL7R p.(Val138Ilefs*10), and ITGB2 p.(Ser627Valfs*61), and one previously reported in ITGB2 p.(Cys62*). In one of the families, two variants in two different genes, including DNAH6 p.(Tyr2653His) and NIPAL4 p.(Gly121Ser), were detected in an unclassified patient. All the identified variants were found in a homozygous state in the patient but in a heterozygous state in the available parents. The study will facilitate the diagnosis and management of IEI patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University Islamabad, Islamabad, Pakistan.
- Department of Biochemistry, Federal Medical & Dental College, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.
- Department of Pediatrics, Pakistan Institute of Medical Sciences Islamabad, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.
- Department of Immunology, Armed Forces Institute of Pathology, Combined Military Hospital, Rawalpindi, Pakistan.
- HBS Medical and Dental College, Islamabad, Pakistan.
- Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University Islamabad, Islamabad, Pakistan. imranullah@qau.edu.pk.
ORCID-Profile: Imran Ullah
Zitieren
APA
Fayyaz, H., Zaman, A., Haider, N., Waris, R., Hussain, M., Raza, S. I., Ahmad, W., & Ullah, I. (2024). Sequence variants underlying severe combined immunodeficiency and leukocyte adhesion deficiency type 1 in six consanguineous families. Immunogenetics. https://doi.org/10.1007/s00251-024-01353-9
Vancouver
Fayyaz H, Zaman A, Haider N, Waris R, Hussain M, Raza SI, et al. Sequence variants underlying severe combined immunodeficiency and leukocyte adhesion deficiency type 1 in six consanguineous families. Immunogenetics. 2024. doi:10.1007/s00251-024-01353-9
BibTeX
@article{Fayyaz2024,
author = {Fayyaz, Hajra and Zaman, Atteaya and Haider, Nighat and Waris, Rehmana and Hussain, Muhammad and Raza, Syed Irfan and Ahmad, Wasim and Ullah, Imran},
title = {Sequence variants underlying severe combined immunodeficiency and leukocyte adhesion deficiency type 1 in six consanguineous families},
journal = {Immunogenetics},
year = {2024},
doi = {10.1007/s00251-024-01353-9}
}
EUVIMED